Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

YOU WONT BELIEVE: Arcturus rapeutics - What They Never Told You

Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022

CSL paying $312m to license mRNA vax tech

CSL paying $312m to license mRNA vax tech

CSL Seqirus is paying $A312 million up-front to license next-generation mRNA technology from a small US company, Arcturus Therapeutics.

Arcturus Therapeutics's Return On Capital Employed Overview

Arcturus Therapeutics's Return On Capital Employed Overview

Benzinga Pro data, Arcturus Therapeutics (NASDAQ:ARCT) reported Q1 sales of $5.24 million. Earnings fell to a loss of $51.17 million, resulting in a 32.35% decrease from last quarter.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022

Expert Ratings for Arcturus Therapeutics

Within the last quarter, Arcturus Therapeutics (NASDAQ:ARCT) has observed the following analyst ratings:

Arcturus Therapeutics's Earnings Outlook

Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that Arcturus Therapeutics will report an earnings per share (EPS) of $-1.44.

Arcturus Therapeutics's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $5.79 million. Earnings were up 28.51%, but Arcturus Therapeutics still reported an overall loss of $38.66 million.

inkl

Read news from The Economist, FT, and more,
with one subscription

Arcturus Therapeutics's Earnings Outlook

Arcturus Therapeutics's Earnings Outlook

Arcturus Therapeutics (NASDAQ:ARCT) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement. Analysts estimate that Arcturus Therapeutics will report an earnings per share (EPS) of $-1.72.

1

Organisations

Activision Blizzard

Palo Alto Networks

Coinbase Global

Rigetti Computing

TakeTwo Interactive

Truist Securities

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

390,696 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play